The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A Role for Fractalkine and Its Receptor (CX3CR1) in Cardiac Allograft Rejection
Abstract
The hallmark of acute allograft rejection is infiltration of the inflamed graft by circulating leukocytes. We studied the role of fractalkine (FKN) and its receptor, CX3CR1, in allograft rejection. FKN expression was negligible in nonrejecting cardiac isografts but was significantly enhanced in rejecting allografts. At early time points, FKN expression was particularly prominent on vascular tissues and endothelium. As rejection progressed, FKN expression was further increased, with prominent anti-FKN staining seen around vessels and on cardiac myocytes. To determine the capacity of FKN on endothelial cells to promote leukocyte adhesion, we performed adhesion assays with PBMC and monolayers of TNF-α-activated murine endothelial cells under low-shear conditions. Treatment with either anti-FKN or anti-CX3CR1-blocking Ab significantly inhibited PBMC binding, indicating that a large proportion of leukocyte binding to murine endothelium occurs via the FKN and CX3CR1 adhesion receptors. To determine the functional significance of FKN in rejection, we treated cardiac allograft recipients with daily injections of anti-CX3CR1 Ab. Treatment with the anti-CX3CR1 Ab significantly prolonged allograft survival from 7 ± 1 to 49 ± 30 days (p < 0.0008). These studies identify a critical role for FKN in the pathogenesis of acute rejection and suggest that FKN may be a useful therapeutic target in rejection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new class of membrane-bound chemokine with a CX3C motif
Bazan, J. F., Bacon, K. B., Hardiman, G., Wang, W., Soo, K., Rossi, D., Greaves, D. R., Zlotnik, A., & Schall, T. J. (1997) · Nature · doi:10.1038/385640a0 · Cited by 2,013
Cited by
Bachelerie, F., Ben-Baruch, A., Burkhardt, A. M., Combadiere, C., Farber, J. M., Graham, G. J., Horuk, R., Sparre-Ulrich, A. H., Locati, M., Luster, A. D., et al. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.007724 · Cited by 850
Hundhausen, C., Misztela, D., Berkhout, T. A., Broadway, N., Saftig, P., Reiss, K., Hartmann, D., Fahrenholz, F., Postina, R., Matthews, V., et al. (2003) · Blood · doi:10.1182/blood-2002-12-3775 · Cited by 713
Garton, K. J., Gough, P. J., Blobel, C. P., Murphy, G., Greaves, D. R., Dempsey, P. J., & Raines, E. W. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m106434200 · Cited by 639
Bulenger, S., Marullo, S., & Bouvier, M. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.01.004 · Cited by 448
Li, L., Huang, L., Sung, S.-S. J., Vergis, A. L., Rosin, D. L., Rose, C. E., Lobo, P. I., & Okusa, M. D. (2008) · Kidney International · doi:10.1038/ki.2008.500 · Cited by 393
Fractalkine (CX3CL1) as an amplification circuit of polarized Th1 responses
Fraticelli, P., Sironi, M., Bianchi, G., D’Ambrosio, D., Albanesi, C., Stoppacciaro, A., Chieppa, M., Allavena, P., Ruco, L., Girolomoni, G., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11517 · Cited by 321
Fractalkine in Vascular Biology: From Basic Research to Clinical Disease
Umehara, H., Bloom, E. T., Okazaki, T., Nagano, Y., Yoshie, O., & Imai, T. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000095360.62479.1f · Cited by 319
Ishida, Y., Gao, J.-L., & Murphy, P. M. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.569 · Cited by 310
McDermott, D. H., Fong, A. M., Yang, Q., Sechler, J. M., Cupples, L. A., Merrell, M. N., Wilson, P. W. F., D’Agostino, R. B., O’Donnell, C. J., Patel, D. D., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci16790 · Cited by 281
Self-citationHepatic platelet and leukocyte adherence during endotoxemia
Croner, R. S., Hoerer, E., Kulu, Y., Hackert, T., Gebhard, M.-M., Herfarth, C., & Klar, E. (2006) · Critical Care · doi:10.1186/cc3968 · Cited by 275
CX 3 C Chemokine Fractalkine in Pulmonary Arterial Hypertension
Balabanian, K., Foussat, A., Dorfmüller, P., Durand-Gasselin, I., Capel, F., Bouchet-Delbos, L., Portier, A., Marfaing-Koka, A., Krzysiek, R., Rimaniol, A.-C., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2106007 · Cited by 274
Chemokines and chemokine receptors are involved in the resolution or progression of renal disease
Anders, H.-J., Vielhauer, V., & Schlöndorff, D. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00750.x · Cited by 270
Vascular Remodeling in Transplant Vasculopathy
Mitchell, R. N., & Libby, P. (2007) · Circulation Research · doi:10.1161/01.res.0000261982.76892.09 · Cited by 268
Hughes, P. M., Botham, M. S., Frentzel, S., Mir, A., & Perry, V. H. (2002) · Glia · doi:10.1002/glia.10037 · Cited by 252
“The protective effects of the anti-CX3CR1 antibody in preventing cardiac allograft rejection occurred without marked alteration in the extent of the inflammatory infiltrate in the early stages of graft rejection (Robinson et al., 2000).”
BackgroundThe CX3C chemokine fractalkine in allergic asthma and rhinitis
Rimaniol, A.-C., Till, S. J., Garcia, G., Capel, F., Godot, V., Balabanian, K., Durand-Gasselin, I., Varga, E. M., Simonneau, G., Emilie, D., et al. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.09.041 · Cited by 87
Metadata
- Authors
- Robinson, L. A., Nataraj, C., Thomas, D. W., Howell, D. N., Griffiths, R., Bautch, V., Patel, D. D., Feng, L., & Coffman, T. M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-12-01
- Volume
- 165
- Issue
- 11
- Pages
- 6067-6072
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2160886090
- Cited by
- 166
- References
- 1
- FWCI
- 19.12
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.